CS First Boston Lowers Merck to 'Underperform'

Analyst Ken Kulju expects the drug giant's shares to continue to struggle for the rest of the year

CS First Boston downgraded Merck & Co. (MRK ) to underperform from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.